AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q3 2013 Earnings Presentation

22 slides from AMAG Pharmaceuticals's earnings presentation, Oct 23, 2013

  1. Slide 1: Third Quarter 2013 Financial Results

    Third Quarter 2013 Financial Results AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham, MA 02451 o 617.498.3300 www.amagpharma.com A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO IMPROVING THE QUALITY OF PATIENTS’ LIVES.

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements 1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to: impro

  3. Slide 3: Agenda

    Agenda Topic Speaker Opening Remarks Bill Heiden, CEO Financial Highlights & Outlook Frank Thomas, COO Commercial Performance Greg Madison, CCO Expansion Opportunities and Closing Remarks Bill Heiden, CEO 2 Copyright © 2013 AMAG Pharmaceuticals. All Rights Reserved.

  4. Slide 4: Third Quarter 2013 Highlights

    Third Quarter 2013 Highlights 3 Outstanding 3Q13 financial performance 33% increase in U.S. Feraheme net sales vs. 3Q12 driven by volume and net revenue per gram growth Improving Feraheme gross margins Solid management of operating expenses Generated positive cash flow Accelerated growth for Ferahem

  5. Slide 5: Financial Overview

    FINANCIAL OVERVIEW

  6. Slide 6: Feraheme Performance

    Feraheme Performance 5 Net ex-factory sales ($ in millions) Copyright © 2013 AMAG Pharmaceuticals. All Rights Reserved.

  7. Slide 7: Third Quarter Financial Highlights

    Third Quarter Financial Highlights ($ in millions, except per share) 3Q13 3Q12 U.S. Feraheme Sales, Net* $18.7* $14.1** Total Revenues $21.6 $17.7 Feraheme Gross Margin $16.2 $9.8*** R&D Expenses $4.5 $5.3 SG&A Expenses $14.9 $12.2 Net Loss $(0.1) $(4.0) Loss Per Basic Share $(0.01) $(0.19) Cash and

  8. Slide 8: 2013 Revised Financial Outlook

    2013 Revised Financial Outlook ($ in millions) Original 2013 Guidance 2Q13 Update 3Q13 Update U.S. Feraheme sales, net $63 - $67 $67 - $70 $69 - $71* Total revenues $73 - $77 $77 - $80 $78 - $81 Feraheme COGS (% of global net sales) 14% - 18% 14% - 18% 15% - 17% Operating Expenses $78 - $82 $78 - $8

  9. Slide 9: Positive Trends on Key Financial Metrics

    Positive Trends on Key Financial Metrics 8 R&D Copyright © 2013 AMAG Pharmaceuticals. All Rights Reserved.

  10. Slide 10: U.S. Commercial Performance

    U.S. COMMERCIAL PERFORMANCE

  11. Slide 11: Current US Non-Dialysis IV Iron Market

    Current US Non-Dialysis IV Iron Market >$400 million (Feraheme Dollars)* 10 50% of market is for treatment of patients with CKD Primary sites of treatment are hematology/oncology clinics and hospitals * Sources: IMS Health IV iron market data; Market opportunity estimated by AMAG at >$500/gram (500,

  12. Slide 12: Today's Commercial Objective: Increase Share of Current IV Iron Market

    Today’s Commercial Objective: Increase Share of Current IV Iron Market 11 Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and D

  13. Slide 13: Accelerating Feraheme Demand Growth

    Accelerating Feraheme Demand* Growth 12 * Source: IMS Health Data. Evolution Index (E.I.) of 120 Growing +20% above market growth and taking share from the competition 32%

  14. Slide 14: Feraheme Demand Growth by Segment

    Feraheme Demand* Growth by Segment 13 3Q13 Market Share 17% of non-dialysis IV iron market (+2% point vs. 2Q13) 10% of hospital segment; E.I. 118 30% of hem/onc segment; E.I. 115 Contracting strategy drove increased hem/onc share in third quarter *Source: IMS Health Data. Copyright © 2013 AMAG Pharm

  15. Slide 15: MuGard Commercial Integration

    MuGard Commercial Integration MuGard is a prescription oral rinse for the management of oral mucositis Approximately 40% of patients receiving chemotherapy and radiation therapy at risk of developing oral mucositis (~400,000 patients/year) MuGard has ~1% share of OM patients ~$1,000 net revenue per

  16. Slide 16: Expansion Opportunities

    EXPANSION OPPORTUNITIES

  17. Slide 17: IDA Label Expansion Plans

    Potential IDA approval in EU (milestone to AMAG) PDUFA for broader IDA indication IDA submission in EU sNDA submitted to FDA Global 1,400 patient phase III program completed IDA Label Expansion Plans 16 2013 2012 2014 New Action Date – January 21 Copyright © 2013 AMAG Pharmaceuticals. All Rights Res

  18. Slide 18: Planning for 2014 with potential label expansion: Gain Additional Share

    Planning for 2014 with potential label expansion Opportunity: Gain Additional Share of Existing Market 17 Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, Nati

  19. Slide 19: Planning for 2014 with potential label expansion: Grow IV Iron Market

    18 IV Iron IDA IV Iron IDA-CKD Oral Iron IDA Oral Iron IDA-CKD 4,000,000 patients diagnosed with IDA placed on oral iron therapy IV Iron IDA-CKD IV Iron IDA Planning for 2014 with potential label expansion Opportunity: Grow IV Iron Market Copyright © 2013 AMAG Pharmaceuticals. All Rights Reserved.

  20. Slide 20: Targeting Business Development

    Targeting Business Development 19 Financial Similarly sized (or smaller) specialty company Eliminate overlapping infrastructure and increase EBITDA Bulls-Eye Hem/onc or hospital company or product $10–$60 MM/yr. revenue potential IP runway Immediate accretive Opportunity for growth Strategic Opportu

  21. Slide 21: Building off YTD 2013 Successes

    Building off YTD 2013 Successes Continue significant Feraheme sales growth vs. 2012 Drive market share gains (E.I. +100) and market growth Continue growth of net revenue per gram Expand Feraheme indication: IDA (non-CKD) oral iron failures Expected FDA action – 1Q14 Expected EU action – 1H14 Execute

  22. Slide 22: Well positioned for success in 2013... and beyond

    Well positioned for success in 2013. . . and beyond. AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham, MA 02451 o 617.498.3300 www.amagpharma.com A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO IMPROVING THE QUALITY OF PATIENTS’ LIVES.

AMAG Pharmaceuticals — Q3 2013 Earnings Presentation on 6ix